## Abstract Levodopa is the most effective symptomatic agent in the treatment of Parkinson's disease (PD) and the βgold standardβ against which new agents must be compared. However, there remain two areas of controversy: (1) whether levodopa is toxic, and (2) whether levodopa directly causes motor
Reply: Levodopa in the treatment of Parkinson's disease: Current controversies
β Scribed by C. Warren Olanow; Yves Agid; Yoshi Mizuno
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 74 KB
- Volume
- 20
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The original articles to which this Letter refers have published in Movement Disorders: Current Controversies: Levodopa in the Treatment of Parkinson's Disease, by Sharma, Vassallo, and Ross and Levodopa in the Treatment of Parkinson's Disease: Current Controversies, by Gerlach, Reichmann, and Riederer.
π SIMILAR VOLUMES
## Abstract Companion letters have been published in __Movement__ Disorders: Current Controversies: Levodopa in the Treatment of Parkinson's Disease, by Sharma, Vassallo, and Ross and Reply: Levodopa in the Treatment of Parkinson's Disease, by Olanow, Agid, and Mizuno.
## Abstract Companion letters have been published in __Movement__ Disorders: Levodopa in the Treatment of Parkinson's Disease: Current Controversies, by Gerlach, Reichmann, and Riederer and Reply: Levodopa in the Treatment of Parkinson's Disease, by Olanow, Agid, and Mizuno.
## Abstract The original article to which this Erratum refers was published in the September, 2004 issue of __Movement__ Disorders (2004) 19 (9) 997β1005.